Statement/Regulatory AdmissionFormycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama® 18.11.2024 / 06:30 ...

FRANKFORT, IL / ACCESSWIRE / November 17, 2024 / Hometown NP, co-founded by Dr. Chime Ajiere, DNP, in 2023, is a leading telehealth practice specializing in telepsychiatric care. The organization is ...

LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it had received clinical trials authorisation for its first in ...

Actress and singer Victoria Summer, who also serves as an ambassador for Teen Cancer America, hosted the evening with a ...

The U.S. healthcare revenue cycle management (RCM) outsourcing market for outpatient and ancillary services is experiencing ...

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

Quotient Sciences, a leading global drug development and manufacturing accelerator, today announced the installation of Centillion’s™ proprietary Biofoundry-in-a-Box (BiaB™), the first multi-product ...

Medtronic receives CE Mark for its next generation Endoflip TM 300 systemEndoflip TM is an advanced diagnostic tool that can ...

Seasoned Behavioral Health Leader Joins THIRA Health, Strengthening Commitment to Comprehensive Mental Health Care for Women and AdolescentsBELLEVUE, WA / ACCESSWIRE / November 15, 2024 / THIRA Health ...

Aviva Aesthetics provides med spa owners with an alternative to private equity CHICAGO, IL and FULTON, MD / ACCESSWIRE / November 15, 2024 / DuneGlass Capital, a healthcare services-focused ...

Protective clothing has become a vital component of the life sciences industry, where rigorous safety standards are paramount for worker protection and maintaining sterile environments. As research, ...

Primary analysis data in potentially pivotal GBM study with lead program, Berubicin, on track for the first half of 2025Company strengthens cash position to extend runway to fund operations beyond ...